T1	Participants 78 112	advanced nasopharyngeal carcinoma:
T2	Participants 180 256	Nasopharyngeal carcinoma (NPC) is a radiosensitive and chemosensitive tumor.
T3	Participants 368 395	patients with advanced NPC.
T4	Participants 417 557	From December 1993 to April 1999, 284 patients with 1992 American Joint Committee on Cancer stage III to IV (M0) NPC were randomly allocated
T5	Participants 1790 1816	patients with advanced NPC
